Dr. Lal PathLabs Ltd.
|
|
- Giles Gardner
- 6 years ago
- Views:
Transcription
1 Dr. Lal Pathlabs Ltd. (DLP) is a provider of diagnostic and related healthcare tests and services in India. It provides a range of diagnostic and related healthcare services which are used in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. DLP is coming with an initial public offering (IPO) of 11.6mn shares in offering to raise around Rs. 6,380mn, with subscription starting from 08 th Dec The issue will close on 10 th Dec Not more than 50% of the issue will be allocated to qualified institutional buyers (QIBs). Further, not less than 15% of the issue will be available for non-institutional bidders and the remaining 35% for retail investors. Net proceed from the issue will be used for following purpose: The company will not receive any proceeds from the issue. All the proceeds will go to the selling shareholders. To provide liquidity and benefits of listing to the existing shareholders Valuation & Recommendation: DLP is the first healthcare diagnostic company to be listed, hence there are no listed comparable peers. The company has recorded strong financials; i.e top-line, EBITDA and PAT grew by 29.1%, 28.8% and 32.9% CAGR, respectively, over FY Over the same period, EBITDA and PAT margins stood in the range of 22%-25% and 12%-14%, respectively. Moreover, cash flow from operations increased by 23.7% CAGR. RoE stood in the range of 28%-38%. At higher price band, the company s shares are available at a P/E multiple of 48.4x to its FY15 earnings, which seems to be stretched, but given its strong profitability, cash flow generation capacity; brand name and low capex business model, we feel the demanded valuation justified. Thus we recommend investors to SUBSCRIBE for the issue. Recommendation Price Band Rs Rs. 550 Retail Discount Rs. 15 per share Total Issue Size (OFS) Rs. 6,380mn SUBSCRIBE Bidding Date 08 th Dec. 10 th Dec Book Running Lead Manager Registrar Sector/Industry Promoters Kotak Mahindra Capital Company Ltd. and Citigroup Global Markets India Pvt. Ltd. Link Intime India Pvt. Ltd. Healthcare (Hony.) Brig. Dr. Arvind Lal, Dr. Vandana Lal and Eskay House (HUF) Shareholding Pattern Pre-Issue Post-Issue Promoters 63.7% 58.7% Institutions 32.2% 23.2% Non-Institution 4.1% 18.1% Total 100.0% 100.0% Retail Application Money at Higher Cut-Off Price per Lot Number of Shares per Lot 20 Application Money Rs. 10,700 Cheque Payable to Dr Lal PathLabs Public Issue Escrow - R Sahil Nandkumar Equity Research Analyst ( ; Ext: 914) sahil.nandkumar@choiceindia.com FY11 FY12 FY13 FY14 FY15 H1 FY16 Total Operating Revenue 2, , , , , ,050.4 Total Operating Expenditure (1,806.3) (2,557.0) (3,540.1) (4,193.9) (5,036.4) (3,195.0) EBITDA , , Depreciation Charge (136.0) (198.3) (204.0) (272.3) (281.9) (135.9) Finance Cost (7.8) (25.3) (4.4) (2.0) (4.1) (1.9) Finance Income Other Income Exceptional Item (166.3) Reported PAT , , Restated EPS (Rs.) Restated BVPS (Rs.) EBITDA margin (%) 24.1% 25.5% 22.1% 25.1% 24.0% 21.6% Reported PAT Margin (%) 12.4% 13.2% 12.2% 14.3% 14.3% 9.2% RoE (%) 31.8% 38.9% 34.3% 34.7% 27.9% 9.2% RoCE (%) 36.5% 52.6% 44.4% 44.5% 35.9% 17.2% * Represents per share calculation based on number of shares o/s post issue; IPO UPDATE 1
2 Healthcare Market in India: Underpenetrated Healthcare Markets: As per the Global Health Expenditure database compiled by the World Health organization, India s total expenditure on healthcare stands at 4% of its gross domestic product (GDP) as of India not only trails behind developed countries in terms of healthcare spending as portion of GDP, but also developing countries such as Brazil, Russia, China and Thailand. This is primarily due to under-penetration of healthcare services and lower consumer spending on healthcare. The government s expenditure on healthcare also ranks lower than other developing countries in terms of general government expenditure on health as a percentage of total expenditure Total Healthcare Expenditure as % of GDP (2013) Expanding Healthcare delivery Industry: CRISIL Research estimates the Indian healthcare delivery industry at Rs. 3.8tn in FY15 and expects it to grow at a CAGR of 12% and be worth Rs. 6.8tn by FY20. The increase is expected due to changes in demographics, penetration of health insurance, health awareness, rising incomes and increasing opportunities for medical tourism. Indian Diagnostic Industry Diagnostic industry provides useful information for the correct treatment of patient diseases, the services make up a low share of the overall healthcare spends. The industry can be classified into imaging diagnostics and pathology testing services. CRISIL estimated the size of the industry to be at Rs. 377bn in FY15 and expects it to be over Rs. 600bn by FY18 (i.e. CAGR of 16.8%). Pathology business accounts for major share of diagnostic industry due to lower price and increase in prescription. Urban Diagnostic 67% Rural Diagnostic 33% IPO UPDATE 2
3 Indian Diagnostic Industry (Contd ): India s urban population (28%) contributes up to 67% of the overall diagnostic market revenue. CRISIL Research believes that towns having populations of 0.3mn-1mn are underserviced in terms of diagnostic centers, have the potential to be served in the long term. Demand drivers for the Indian diagnostic Industry: Increase in prescribed diagnostic tests by doctors Demand-supply gap i.e. low penetration of healthcare facilities and increasing demand Growth of lifestyle diseases such as cardiac diseases, diabetes, cancer are expected to boost demand for diagnostic services Rising income levels make quality healthcare services affordable Increasing population and improving life expectancy Business Model of diagnostic centers in India: Diagnostic centers in India can be classified into three types; hospital- based centers, diagnostic chains and standalone centers. They operate in two business segments i.e. pathology and radiology. Below are the business models adopted by the diagnostic centers: Hospital based: Diagnostic centers located within hospitals. Mostly owned by hospital: are also given to third parties to manage Diagnostic Chains: Privately owned diagnostic centers with two or more centers. Operate mostly through a hub & spoke model of collection centers. They adopt the hub & spoke model to expand their networks, which helps to maximize revenues Standalone Centers: They are diagnostic centers with a single center. Majority have a small scale of operations and offer basic diagnostic tests. IPO UPDATE 3
4 Indian Diagnostic Industry (Contd ): The diagnostic industry in India is a highly fragmented industry with the standalone centers commanding 48% market share followed by the Hospital based labs (37%) and Diagnostic chains (15%). Diagnostic Chains to eat into market share of standalone centers: Diagnostic chains have grown rapidly with the emergence of pan-india players. Historically, standalone diagnostic centers and hospital based diagnostics have dominated the industry. However, modern management tools and private capital have facilitated the expansion of some of the standalone centers since 2000, leading to emergence of large chains. The success of many large chains has also encouraged smaller regional players to adapt the hub & spoke model. Key Factors for success of Diagnostic centers: Establishing strong brand name, as it helps to increase patient walk-ins Wide network of satellite labs and collection centers aligned through the hub and spoke model Strong logistics network, so as to reduce turnaround time from sample collection to final report generation Tie ups with multiple sources so as to generate steady volumes of tests in the initial growth phase of the network in a given region Adopting latest technology and proper maintenance of equipment to ensure quality and accuracy of tests Location is critical for the success of a diagnostic center, hence factors such as competition, age profile and income demographics of target customers should be considered IPO UPDATE 4
5 Company Introduction: DLP is a provider of diagnostic and related healthcare tests and services in India. It provides a range of diagnostic and related healthcare services which are used in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The customers include individual patients (largest customer group), corporate customers, hospitals and other healthcare providers. Diagnostics healthcare testing is an essential element in the delivery of healthcare services, as it provides healthcare service providers with useful information for the diagnosis and treatment of diseases. The company offers over 3,495 diagnostic and related healthcare tests and services which include; (i) routine clinical laboratory tests -such as blood chemistry analyses and blood cell counts; (ii) specialized testing services -such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and (iii) preventive testing services-such as screenings for hypertension, heart disease and diabetes. These tests are performed using sophisticated and computerized instruments in the company s clinical laboratories. DLP s Infrastructure FY13 FY14 FY15 H1 FY16 Clinical Laboratories Total Patient Service Centers 824 1,064 1,340 1,554 Owned patient Service Centers Franchisee patient Service Centers 776 1,009 1,271 1,475 Pickup Points 2,879 4,225 5,667 7,059 As of 30th Sept. 2015, the company has built a national hub and spoke network, that includes its National Reference laboratory in New Delhi, 171 other clinical laboratories, 1,554 patient service centers and 7,059 pickup points. The hub & spoke model, whereby specimens are collected across multiple locations within a region for delivery to a pre designated clinical laboratory for centralized diagnostic testing, provides greater economies of scale and offers a scalable platform for the continued growth. DLP provides pan India services including in large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. The company also has a centralized information technology platform which fully integrates its large network through a common logistics & payments system and tracks operations & internal performance metrics, thereby enabling it to improve the business efficiency. DLP has a sales team of 498 personnel who are divided into two strategic business units, one covering Delhi, certain states of North India and international business, and the other covering rest of India. Most of the laboratories equipment and instruments are acquired from vendors under reagent rental agreements, unless the equipment is not available under such an agreement or the agreement is less cost effective. Some of the major diagnostic laboratory services provider from which the company faces competition are; Fortis/SRL, Metropolis and Thyrocare. DLP has 12 registered trademarks and eight copyright registrations, moreover, it has also applied for the registration of 36 trademarks. IPO UPDATE 5
6 Company Introduction (Contd ): As of 30th September 2015, the company has 3,253 full time employees and 83 full time consultants engaged on a contractual basis including pathologists, phlebotomists and radiologists, located in India. At present, DLP receives specimens for diagnostic testing at its clinical laboratories in India from the following countries; Bhutan, Sri Lanka, Nepal, Bangladesh, Myanmar, the United Arab Emirates, Oman, Qatar, Kuwait, Kenya, Tanzania and Nigeria. It has no laboratories or testing facilities outside India. However, it is planning to expand its clinical laboratory beyond India. Geographical Revenue Break-up Zone FY13 FY14 FY15 H1 FY16 North India 3, , , ,955.6 East India South India West India International Total 4, , , ,050.0 The company believes that its focus on customers is a critical differentiator in the diagnostic and healthcare industries and, together with its brand recognition for quality services, results in individuals and healthcare providers choosing DLP as their diagnostic healthcare service provider. In FY15 and the six period ended Sep. 30, 2015, the company collected and processed approx 21.8mn samples and 13.4mn samples from approx 9.9mn and 6.2mn patients, respectively. IPO UPDATE 6
7 Competitive Strengths: Established consumer healthcare brand with focus on quality services to customers: DLP focuses on providing quality diagnostic healthcare services. It offers patient convenient locations for diagnostic healthcare services and efficient service. The company believes that its focus on patients as customers is a critical differentiator in the industry as; (i) in India, patients generally choose their diagnostic healthcare service provider and (ii) patients and healthcare providers seek quality healthcare service providers. Well positioned to leverage upon one of the fastest growing segments of the Indian healthcare industry: As of Sept. 30, 2015, the companies network consist of a National reference laboratory, 171 other clinical laboratories and 1,554 patient services centers. The network has coverage across India, including metropolitans such as New Delhi, Mumbai, Bengaluru and Chennai. The combination of its long operating history, nationwide network and reputation for quality services positions DLP well to take advantage of the Indian diagnostic healthcare service industry. Combination of Hub & spoke model and instrument leasing model: With increase in size of the network, the company is able to achieve greater economies of scale. DLP has incorporated an hub & spoke model, which is scalable and thus provides opportunities for future growth of the business. The reagent rental model (Instrument leasing model) provide economic benefit by lowering capital expenditure for diagnostic equipment as no payment is made on receiving the equipment, but instead the amount is effectively amortized through purchase of reagent inputs necessary to perform the test and services. Scalable and fully integrated Information technology platform: DLP s centralized information technology platform fully integrates its large network through a common logistics and payments system, enabling it to collect sample and payments more efficiently. The centralized technology gives healthcare providers convenient, online access to diagnostic results. The growth of its network is supported by the scalability of its technology platform, which can readily adapt to the increased data requirement of additional clinical laboratories and patient service center. Strong Financial performance: Between FY13-15, top-line grew from Rs. 4,544.8mn to Rs. 6,625.2mn (CAGR of 20.7%), EBITDA margin grew from 22.1% to 24% and profit grew from Rs mn to Rs. 950mn (CAGR of 30.7%). The company has a low level of indebtedness. The attractive financial performance is due to growth of network, expansion of tests and services, improvements in operational efficiency, low capital expenditure model and the strategy of prioritizing resources and investments in accordance with importance to business. Business Strategies: Expand market presence: DLP intends to strength its presence in regions in which it operates, with particular emphasis on its core markets of North India as well as Central and Eastern India by opening new franchised patient service centers and regional reference laboratories. The company also has an expansion plans in Southern and Western India by opening additional clinical laboratories and patient service centers. DLP also intends to continue explore expansion opportunities in India through strategic acquisitions and partnership with regional diagnostic healthcare service providers. Increase the breadth of diagnostic healthcare testing and services platform: The company plans to increase the breadth of its diagnostic healthcare testing and services platform through, among other things, the adoption of new, cutting-edge diagnostic healthcare testing technology, as it expects this to increase it sources of revenue and enhance its reputation. It also intends to further grow its corporate customer base by continuing to market its health proposition to corporate decision makers. Continued focus on providing quality services: DLP will continue to focus on the quality and reliability of its diagnostic related healthcare services as it is essential for the success. It will also continue to upgrade technology in order to increase the processing capacity efficiency. The company will also enhance customer experience by further developing its online initiatives and leveraging potential data analytics capabilities. Leverage network efficiency to expand hospital based and other clinical laboratories: DLP plans to increase the number of hospital based clinical laboratories by leveraging the scale and efficiency of its existing network to perform the diagnostic healthcare testing services of these hospitals and other clinical laboratories. The company may seek tie ups with polyclinics as these clinics have limited resources, thus presenting an opportunity for both laboratory management and specialized laboratory testing services. IPO UPDATE 7
8 Risk and Concerns: Intense competition: India s diagnostics industry is highly competitive with standalone centers having close to a 48% market share, compared to around 37% for hospital-based diagnostic centers. This increases competition for organized diagnostic chains in terms of volumes of patients samples and aggressive pricing of diagnostic tests. Geographical concentration: Many small diagnostic chains operating three or four labs in a particular location or region are susceptible to the supply and demand dynamics of that specific location. Shortage of manpower: Key area of concern is the training and retention of critical staff such as lab technicians, who are employed at labs and collections centers and are responsible for the collection and preservation of patient samples. The situation is even more critical for standalone diagnostic centers, which may not be able to employ well-trained lab technicians and pathologists. Vulnerable to technological advancements: To stay ahead of the competition, diagnostics centers have to constantly upgrade their technology. However, these upgrades not only involve significant capital investments but also increase maintenance costs. This significantly increases cost overheads for service providers. Moreover, two versions of certain equipment could have a significant price differential, making it difficult for service providers to upgrade. This is especially the case for smaller players who face a paucity of funds. IPO UPDATE 8
9 Consolidated Financial Statements: Consolidated Profit and Loss Statement Particulars (Rs. mn) FY11 FY12 FY13 FY14 FY15 H1 FY16 Revenue from Operations 2, , , , , ,050.4 Cost of reagents, chemicals, surgical and laboratory supplies consumed (608.7) (761.7) (973.0) (1,176.6) (1,391.6) (881.1) Employee benefit expenses (377.9) (537.7) (938.0) (1,015.7) (1,343.9) (924.6) Other Expenses (819.8) (1,257.6) (1,629.1) (2,001.6) (2,300.9) (1,389.4) EBITDA , , Depreciation and Amortization (136.0) (198.3) (204.0) (272.3) (281.9) (135.9) EBIT , , Finance Cost (7.8) (25.3) (4.4) (2.0) (4.1) (1.9) Finance Income Other Income Exceptional Item (166.3) EBT , , Tax Expenses (151.9) (212.6) (245.5) (389.4) (447.0) (268.4) Reported PAT Consolidated Balance Sheet Particulars (Rs. mn) FY11 FY12 FY13 FY14 FY15 H1 FY16 Share Capital Reserves & Surplus , , , , ,268.6 Minority Interest Long Term Borrowings Deferred Tax Liabilities (Net) Trade Payables Other Long Term Liabilities Long Term Provisions Short Term Borrowings Trade Payables Other Current Liabilities Short Term Provisions Total Liabilities 1, , , , , ,788.8 Goodwill (On Consolidation) Tangible Fixed Assets Intangible Fixed Assets Capital Work in Progress Intangible Assets Under Development Deferred Tax Assets (Net) Long Term and Advances Other Non Current Assets Current Investments Inventories Trade Recievables Cash And Bank Balance , , ,532.8 Short Term Loans And Advances Other Current Assets Total Assets 1, , , , , ,788.9 IPO UPDATE 9
10 Consolidated Financial Statements (Contd ): Cash Flow Statement Particulars (Rs. mn) FY11 FY12 FY13 FY14 FY15 H1 FY16 Net Profit Before Tax , , Depreciation / amortization Interest expense Interest income (17.2) (14.5) (5.7) (58.4) (94.1) (65.0) Others Change in Working Capital 1.8 (0.4) (28.1) (94.5) (321.2) (164.9) Taxes Paid (164.6) (204.6) (334.0) (502.6) (534.3) (248.5) Cash Flow from Operating Activities Purchase of Fixed Assets (240.7) (211.3) (196.2) (327.6) (352.9) (194.9) Interest Received Others 27.7 (66.8) (460.5) (598.2) (625.8) (594.3) Cash Flow from Investing Activities (185.9) (262.6) (650.4) (896.9) (895.3) (766.3) Proceeds from Issuance of Equity Share Capital Equity Shares Bought Back (240.0) (66.0) Proceeds of Long-Term Borrowings (Repayment) of Long-Term Borrowings (0.1) (124.7) - (4.9) - - (Repayment) Proceeds of Short Term Borrowings (141.7) (8.7) - Interest Paid (8.8) (24.5) (1.7) (5.3) (0.5) (0.4) Dividend Paid Including Dividend Tax (149.4) (96.5) (149.9) (96.6) (104.2) (150.0) Cash Flow from Financing Activities (221.5) (383.4) (148.0) (102.0) (8.0) (34.7) Net Cash Flow (24.9) 75.2 (84.7) Opening Balance of Cash and Cash Equivalents Closing Balance of Cash and Cash Equivalents IPO UPDATE 10
11 Financial Statements (Contd ): Consolidated Financial Ratios Particulars (Rs. mn) FY11 FY12 FY13 FY14 FY15 Revenue Growth Rate (%) 44.1% 32.5% 23.3% 18.3% EBIDTA Growth Rate (%) 52.1% 15.0% 40.1% 12.8% EBIDTA Margin (%) 24.1% 25.5% 22.1% 25.1% 24.0% EBIT Growth Rate (%) 54.1% 18.6% 41.8% 15.1% EBIT Margin (%) 18.4% 19.7% 17.6% 20.3% 19.7% Reported PAT Growth Rate (%) 52.9% 23.2% 44.2% 18.4% Reported PAT Margin (%) 12.4% 13.2% 12.2% 14.3% 14.3% Liquidity Ratios Current Ratio Quick Ratio Interest Coverage Ratio Debt to Equity Ratio Net Debt to EBITDA (0.1) (0.2) (0.8) (0.8) (1.2) Net Debt to Equity (0.1) (0.2) (0.5) (0.5) (0.5) Turnover Ratios Inventory Turnover Ratio Receivable Turnover Ratio Accounts Payable Turnover Ratio Fixed Asset Turnover Ratio Total Asset Turnover Ratio Return Ratios RoE (%) 31.8% 38.9% 34.3% 34.7% 27.9% RoCE (%) 36.5% 52.6% 44.4% 44.5% 35.9% Per Share Data Restated EPS Restated BVPS Restated Cash EPS Restated Operating Cash Flow per Share * Represents per share calculation based on number of shares o/s post issue; IPO UPDATE 11
12 Choice s Rating Rationale The price target for a large cap stock represents the value the analyst expects the stock to reach over next 12 months. For a stock to be classified as Outperform, the expected return must exceed the local risk free return by at least 5% over the next 12 months. For a stock to be classified as Underperform, the stock return must be below the local risk free return by at least 5% over the next 12 months. Stocks between these bands are classified as Neutral. es Disclaimer This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this recommendation or any action taken on basis of this information. This report is based on the fundamental analysis with a view to forecast future price. The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Choice Broking has based this document on information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended purely for stock market investment purposes. The recommendations are valid for the day of the report and will remain valid till the target period. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee against the loss of your entire investment. POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement Analyst interest of the stock /Instrument(s): - No. Firm interest of the stock / Instrument (s): - No CHOICE INSTITUTIONAL RESEARCH Choice Equity Broking Pvt. Ltd. Choice House, Shree Shakambhari Corporate Park, Plt No: , J.B. Nagar, Andheri (East), Mumbai IPO UPDATE 12
Dr Lal PathLabs Limited Corporate Presentation
Dr Lal PathLabs Limited Corporate Presentation Q4 & FY16 Table of Contents 1 Our Evolution 2 Dr Lal PathLabs at a glance 3 Investment Highlights 4 Key Q4 & FY16 Highlights 5 Notes to Accounts 6 Q4 & FY16
More informationSUBSCRIBE To ASTRON PAPER & BOARD MILL LTD. Growing business at reasonable valuation
SUBSCRIBE To ASTRON PAPER & BOARD MILL LTD. Growing business at reasonable valuation 12th Dec 2017 Salient features of the IPO: Astron Paper and Board Mill Lmt. (APBML), incorporated in 2010, is engaged
More informationInitiating Coverage. Dr Lal Path Labs Ltd. 1 P a g e. related healthcare tests and services in India. Dr Lal Path Labs has strong.
4 Recommendation BUY Dr Lal Path Labs (DLPL) is India s second largest provider of diagnostic and related healthcare tests and services in India. Dr Lal Path Labs has strong CMP Rs 973 pedigree of promoters.
More informationDr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018
Dr. Lal PathLabs Limited (DLPL) Q1 FY19 Results Presentation August 10, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials,
More informationDr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018
Dr. Lal PathLabs Limited (DLPL) Q3 & 9M FY18 Results Presentation February 08, 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation
More informationTrident Ltd. Buy & Add on dips
Trident Ltd. Buy & Add on dips 33,351.8 38,689.6 37,553.3 36,656.6 46,944.2 18-Apr-17 18-May-17 18-Jun-17 18-Jul-17 18-Aug-17 18-Sep-17 18-Oct-17 18-Nov-17 18-Dec-17 18-Jan-18 18-Feb-18 18-Mar-18 Trident
More informationDr. Lal PathLabs Limited Corporate Presentation
Dr. Lal PathLabs Limited Corporate Presentation August 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to
More informationDr. Lal PathLabs Limited Corporate Presentation
Dr. Lal PathLabs Limited Corporate Presentation November 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree
More informationLarsen & Toubro Ltd.
Reasonably Priced Salient features of the IPO: Larsen and Toubro Infotech Ltd. (L&TIL) is a global IT services and solutions company. Incorporated in 1996, it is headquartered in Mumbai, India. The company
More informationDr Lal PathLabs. Strong, sustainable business model. IPO Review. Price band ICICI Securities Ltd Retail Equity Research. Investment rationale
IPO Review Rating matrix Rating : Subscribe Issue Details Issue Details Issue Opens Issue Closes 8-Dec-15 10-Dec-15 Issue Size ( crore) 626-638 Price Band ( ) 540-550 No. of Shares on Offer (crore) 1.2
More informationDr. Lal PathLabs. Prescriptive-Preventive-Protective, but too expensive. December 04, Institutional Equity Research Pharmaceuticals India
Dr. Lal PathLabs Prescriptive-Preventive-Protective, but too expensive Dr Lal PathLabs (DLPL) is the second largest diagnostic chain in India with 172 clinical laboratories, 1,554 patient service centers
More informationPrice Band: INR
BSE SENSEX S&P CNX 26,169 7,955 Issue Summary Period December 08-10, 2015 Price band (INR) 540 550 Size (INR m) INR6,264-6,380m offer for sale No. of shares (m) 11.6m offer for sale MCap post issue 45.4
More informationDr. Lal PathLabs Limited Corporate Presentation
Dr. Lal PathLabs Limited Corporate Presentation February 2018 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree
More informationAster DM Healthcare Ltd
IPO Note Healthcare Feb 08, 2018 Aster DM Healthcare Ltd Aster DM Healthcare Ltd (ADHL) is one of the largest private healthcare service providers which operates in multiple GCC states and is an emerging
More informationDr. Lal Path Labs Ltd
Health Care-Health Care Facilities & Svcs Bloomberg Code: DLPL IN India Research - Stock Broking Strong Position in North India, Expanding in South and West Regions: Dr. Lal Path Labs is the second largest
More informationDr. Lal PathLabs Ltd.
IPO NOTE SUBSCRIBE Dr. Lal PathLabs Ltd. Nifty 7,954.9 Sensex 26,169.41 ISSUE DETAILS Offer Price Band ` 54-55 Face Value 1 Issue Size (in crs) `62 63 Shares offered (in crs) 1.16 Type Offer for Sale &
More informationBUY SIMPLEX INFRASTRUCTURES LTD SYNOPSIS. CMP Target Price FEBRUARY 28 th Result Update (PARENT BASIS): Q3 FY15
BUY CMP 408.40 Target Price 460.00 SIMPLEX INFRASTRUCTURES LIMITED Result Update (PARENT BASIS): Q3 FY15 FEBRUARY 28 th 2015 ISIN: INE059B01024 Index Details Stock Data Sector Construction & Engineering
More informationSUBSCRIBE to Hindustan Aeronautics Ltd. Invest with mid to long term time horizon
SUBSCRIBE to Hindustan Aeronautics Ltd. Invest with mid to long term time horizon 14 th Mar. 2018 Salient features of the IPO: Hindustan Aeronautics Ltd. (HAL) conferred with the "Navratna" Recommendation
More informationSUBSCRIBE to H.G. Infra Engineering Ltd. Strong player in government s renewed focus sector
SUBSCRIBE to H.G. Infra Engineering Ltd. Strong player in government s renewed focus sector 19 th Feb. 2018 Salient features of the IPO: H.G. Infra Engineering Ltd. (HGIEL) is an infrastructure construction,
More informationASTER DM HEALTHCARE LIMITED IPO Price Band : ` 180 `190. our recommendation avoid
ASTER DM HEALTHCARE LIMITED IPO Price Band : ` 180 `190 our recommendation avoid THE OFFER Issue Open : 12 Feb 2018 to 15 Feb 2018»» Issue Type: Book Built Issue IPO»» Issue Size: Fresh Issue aggregating
More informationDr. Lal PathLabs. Strong growth supports premium valuations
IPO Note Dr. Lal PathLabs Strong growth supports premium valuations Dr Lal PathLabs (DLP) runs diagnostic laboratories chain of 172 pathology labs and 1,554 patience service centers across India. North
More informationAvenue Supermarts Limited
IPO Note Retail March 4, 2017 Avenue Supermarts Limited A retailer with a growth appetite Avenue Supermarts Ltd (ASL), founded in 2002, is the owner of well established supermarket chain D-Mart. ASL is
More informationFuture Supply Chain Solutions Ltd
IPO Note Financials Dec 04, 2017 Future Supply Chain Solutions Ltd Incorporated in 2006, Future Supply Chain Solutions Ltd (FSCSL) is one of the largest third-party logistics service providers in India.
More informationDr Lal PathLabs Ltd. IPO Note. Our View: Subscribe. Sector: Healthcare
IPO Note (Wholly owned subsidiary of Bank of Baroda) Subscribe Dr Lal PathLabs Ltd. Our View: The company is a provider of diagnostic and related healthcare tests and services in India. Through the company
More informationObjects of the Issue
Recommendation SUBSCRIBE Background Price Band Rs. 160 175 Bidding Date Book Running Lead Manager Registrar Sector 18 th Apr 21 th Apr ICICI Sec, Kotak Mahindra Link Intime India Pvt Ltd Retail Application
More informationPSP Projects Ltd. 1 P a g e. Subscribe with Long Recommendation. Term View BACKGROUND
Subscribe with Long Recommendation Term View BACKGROUND Price Band Rs. 205 Rs. 210 (PSP) is a multidisciplinary construction company Bidding Date 17 th Sep - 19 th May 2017 Book Running Lead Manager Registrar
More informationIndustry CMP Recommendation Add on Dips to band Sequential Targets Time Horizon Healthcare Rs. 960 BUY Rs Rs Quarters
INVESTMENT IDEA 31 MAR 2017 Dr. Lal PathLabs Industry CMP Recommendation Add on Dips to band Sequential Targets Time Horizon Healthcare Rs. 960 BUY Rs. 890-960 Rs. 1090-1235 3-4 Quarters HDFC Scrip Code
More informationSouth Indian Bank Ltd.
23-Jun-15 23-Aug-15 23-Oct-15 23-Dec-15 23-Feb-16 23-Apr-16 23-Jun-16 23-Aug-16 23-Oct-16 23-Dec-16 23-Feb-17 23-Apr-17 South Indian Bank Ltd. Q1 FY18 RESULT UPDATE Low provisioning to boost profitability
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 KMC Speciality Hospitals India Ltd CMP: 7.61 January 21, 2015 Stock Details BSE code 524520 BSE ID KMCSHIL Face value
More informationPNB Housing Finance Ltd. Robust play in Indian HFC sector SUBSCRIBE 24th Oct, 2016
PNB Housing Finance Ltd. Robust play in Indian HFC sector SUBSCRIBE 24th Oct, 2016 PNB Housing Finance Ltd (PNBHFL) is the fifth largest housing finance company (in terms of loan portfolio) and the second
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/15 Apr/15 May/15 Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/15 Dec/15 CMP: 43.00 January 11, 2015 Stock Details BSE code 526301 BSE ID MEDINOV Face value ( ) 10 No of shares (m) 9 52 week
More informationSUBSCRIBE. ICICI Lombard General Insurance Co Ltd. Issue Open: Sept 15, 2017 Issue Close: Sept 19, IPO Note Insurance
IPO Note Insurance Sept 14, 2017 ICICI Lombard General Insurance Co Ltd ICICI Lombard is the largest non-life private sector insurer in India. It is a JV between ICICI Bank and Fairfax Financial Holdings
More informationAkzo Nobel India Ltd.
Q2 FY16 RESULT ANALYSIS Akzo Nobel India Ltd. Waiting for revival in demand scenario Buy Nov 3, 2015 Akzo Nobel India Ltd. (AKZO) reported 8% YoY revenue growth in Q2FY16 mainly driven by increase in the
More informationSubscribe with Caution to Varroc Engineering Ltd. Strong fundamentals but valuation not supportive
Subscribe with Caution to Varroc Engineering Ltd. Strong fundamentals but valuation not supportive Salient features of the IPO: Aurangabad-based auto component maker Varroc Engineering Ltd. (Varroc) is
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationReligare Technologies Ltd BSE Scrip Code:
Religare Technologies Ltd BSE Scrip Code: 533525 IT Consulting & Software October 15, 2012 Equity Statistics Current Market Price Rs. 17.05 52 Week High/Low Rs. 44.90/13.70 Market Capitalisation Rs. Crores
More informationSpan Diagnostics Limited
Span Diagnostics Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details October 215 Current Price : ` 96.7^ Face Value : ` 1 per share 52 wk High / Low : ` 96.9 / 42.55 Total Traded
More informationNEUTRAL. Neogen Chemicals Ltd. Issue Open: April 24, 2019 Issue Close: April 26, IPO Note Specialty Chemicals
IPO Note Specialty Chemicals April 22, 2019 Neogen Chemicals Ltd. NEUTRAL Issue Open: April 24, 2019 Issue Close: April 26, 2019 Neogen Chemicals Limited (NCL) is one of the leading Indian manufacturers
More informationWonderla Holidays Limited
IPO Note Rating matrix Rating : Unrated Issue Details Issue opens 21-Apr-13 Issue closes 23-Apr-13 Issue size ( cro re) 166-180 No of share s on offer (crore) 1.45 Fresh Issue 1.45 Employee Reservation
More informationGMR Infrastructure Ltd
July 20, 2017 GMR Infrastructure Limited (GIL) is engaged in generation of power, mining and exploration activities, development of highways, infrastructure development, such as development and maintenance
More informationIPO Product Note October 21, 2016
IPO Product te October 21, 2016 PNB Housing SECTOR Housing Finance Issue Highlights About the Company Issue Open Oct 25, 2016 Issue Close Oct 27, 2016 Issue Price Rs.750 - Rs.775 per share Total Issue
More informationBDH Industries Limited BSE Scrip Code:
BDH Industries Limited BSE Scrip Code: 524828 Pharmaceuticals October 23, 2012 Equity Statistics Current Market Price Rs. 16.95 52 Week High/Low Rs. 21.00/13.15 Market Capitalisation Rs. Crores 9.76 Free
More informationIndian Healthcare Industry
Indian Healthcare Industry 2012 Synopsis Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by Gyan Research and Analytics Pvt. Ltd. (Gyan). While
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationPowerhouse Fitness and Realty Limited
10 February 2016 CMP: Rs.33 Industry: Other Leisure facilities BSE Group/Index: M Promoters Gupta family Year of incorporation 2013 Registered office 702, Plot No. 1, Concord CHS, JVPD Scheme, Vile Parle
More informationTirupati Sarjan Limited
Tirupati Sarjan Limited Date: 5 th January, 216 Stock Performance Details Shareholding Details September 215 Current Price : ` 27.5^ Face Value : ` 5 per share 52 wk High / Low : ` 29.7 / 1.6 Total Traded
More informationCravatex Limited. Stock Performance Details Shareholding Details September 2015
Cravatex Limited Date: 20 th January, 2016 Stock Performance Details Shareholding Details September 2015 Current Price : ` 247.8^ Face Value : ` 10 per share 52 wk High / Low : ` 550.0 / 215.0 Total Traded
More informationSUBSCRIBE. IPO Report HDFC ASSET MANAGEMENT COMPANY LTD. IPO Details. Research Analyst : Astha Jain
IPO Report HDFC ASSET MANAGEMENT COMPANY LTD SUBSCRIBE IPO Details Issue Date 25 th July-27 th July 2018 Price Band 1095-1100/Share Bid Lot 13 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE
More informationIPO NOTE BANDHAN BANK LIMITED
IPO NOTE BANDHAN BANK LIMITED 12 TH -MARCH-2018 Rating: Issue Summary: Price Band (Rs) Face Value (Rs) 10 Market Lot Rs.370-375 per share 40 shares Opens 15 th March, 2018 Closes 19 th march, 2018 Issue
More informationCummins India BUY,ADD ON DIPS,
Cummins India BUY,ADD ON DIPS, 60, 000.00 50, 000.00 40, 000.00 30, 000.00 20, 000.00 10, 000.00 0.0 0 47,961.00 20-Mar-17 20-Apr-17 20-May-17 41,543.80 20-Jun-17 20-Jul-17 20-Aug-17 51,237.50 20-Sep-17
More informationPNB Housing Finance Ltd.
IPO Note: PNB Housing Finance Ltd. Industry: Housing Finance Recommendation: Not Rated Date: October 20, 2016 Company Name PNB Housing Finance Ltd. Issue Opens October 25, 2016 to October 27, 2016 Price
More informationSKS Textiles Limited (NSE SME)
SKS Textiles Limited (NSE SME) IPO Fact Sheet SKS Textiles Ltd. Opening Date January 9 th, 2018 Closing Date January 11 th, 2018 BRLMs Aryaman Financial Services Issue Size Rs. 13.32 Crores Shares 8.88
More informationAmbuja Cements NEUTRAL. Performance Highlights CMP. `184 Target Price - 2QCY2012 Result Update Cement. Quarterly results (Standalone)
2QCY2012 Result Update Cement Ambuja Cements Performance Highlights Quarterly results (Standalone) Y/E Dec. (` cr) 2QCY2012 1QCY2012 % chg qoq 2QCY2011 % chg yoy Net Sales 2,566 2,633 (2.6) 2,173 18.1
More informationPROCTER & GAMBLE HYGIENE & HEALTH CARE LTD Result Update (PARENT BASIS): Q4 FY15
PROCTER & GAMBLE HYGIENE & HEALTH CARE LTD Result Update (PARENT BASIS): Q4 FY15 ISIN: INE179A01014 OCTOBER 5 th 2015 STOCK DETAILS Sector FMCG BSE Code 500459 Face Value 10.00 52wk. High / Low (Rs.) 7435.00/5144.40
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 734.45 Target Price 845.00 WELSPUN INDIA LIMITED Result Update (CONSOLIDATED): Q2 FY16 OCTOBER 24 th 2015 ISIN: INE192B01023 Index Details Stock Data Sector Textiles BSE Code 514162 Face Value
More informationNewgen Software Technologies Ltd
IPO Note IT Jan 12, 2018 Newgen Software Technologies Ltd Incorporated in 1992, Newgen Software Technologies Limited (NSTL) is a New Delhi based IT company and a global provider of Business Process Management
More informationSymphony Ltd. RESULT UPDATE 31st October 2017
. RESULT UPDATE 31st October 2017 Oct-14 Apr-15 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 India Equity Institutional Research II Result Update Q2FY18 II 31st October 2017. CMP INR 1,465 Target INR 1,700 Potential
More informationPrivate Equity and Capital Structuring for optimizing ROI in Healthcare delivery business
Private Equity and Capital Structuring for optimizing ROI in Healthcare delivery business Presented by: Abhay Soi Managing Director, Radiant Life Care Private Limited Introduction Radiant Life Care Private
More informationSBI Life Insurance Co Ltd
SBI Life Insurance Co Ltd Strong parent backing leaves no scope for doubts SBI Life Insurance is a JV between State Bank of India (SBI-70%), and BNP Paribas Cardiff (26%). The insurer s new business premium
More informationOFS: Rs. 82 bn. Rs. 700bn at upper price band JM Financial, Axis Capital, BNP Paribas, Citigroup, Deutsche, ICICI Sec., Kotak, SBI Cap.
SBI Life Insurance Co. Ltd. - Best placed amongst peers in Life insurance industry but expensively valued - SUBSCRIBE for long term.. SBI Life Insurance Company Limited was incorporated at Mumbai on October
More informationAdani Ports & SEZ Rating: Target price: EPS:
Adani Ports & SEZ : price: EPS: Volume traction continues in a seasonally good quarter; maintain Adani Ports & SEZ reported a good quarter with total operating revenues (standalone) of Rs. 8.02bn and PAT
More informationPromoters and Promoter Group Holdings Non Institution 7 -
MUTHOOT FINANCE Ltd. (MFL) IPO note SUBSCRIBE 18 th Apr, 2011 Issue at a Glance Issue Summary Total Issue of Shares (Cr) 5.15 QIB Investors (Cr) 1.80 Non -Institutional Investors (Cr) 0.77 Retail Investors
More informationCompany Overview. Financial Performance
Jan/15 Feb/15 Mar/ Apr/15 May/ Jun/15 Jul/15 Aug/15 Sep/15 Oct/15 Nov/ Dec/15 Parnax Lab Limited CMP: 53.90 January 08, 2016 Stock Details BSE code 506128 BSE ID PARNAXLAB Face value ( ) 10 No of shares
More informationWipro. 3QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 328. Recommendation: Hold
Wipro 3QFY18 Result Update Still not of the woods, maintain Hold Sector: Technology CMP: ` 328 Recommendation: Hold Market statistics Current stock price (`) 328 Shares O/S (cr.) 452.3 Mcap (` cr) 148,571
More informationJenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited Date: 3 rd February, 2016 Stock Performance Details Shareholding Details October 2015 Current Price : ` 418.0^ Face Value : ` 10 per share 52 wk High / Low : ` 542.8 /
More informationCentury Plyboards (I)
Leading branded plywood player Visit note - Not rated 19 June 2014 Institutional Equities Century Plyboard (CPBI), India s leading plywood manufacturer with the highest-selling plywood brand, expects housing
More informationIPO Report ICICI SECURITIES LTD SUBSCRIBE. Valuation. IPO Details. Research Analyst : Astha Jain
IPO Report ICICI SECURITIES LTD SUBSCRIBE IPO Details Issue Date 22 nd Mar-26 th Mar 2018 Price Band 519-520/Share Bid Lot 28 & in multiplethereof Face Value Rs 5/Share Listing BSE, NSE Offer For Sale
More informationPrataap Snacks Limited
IPO Note FMCG September 19, 2017 Prataap Snacks Limited IPO Note Prataap Snacks is one of the top snack food companies in India and with 27% revenue CAGR between FY13-FY17, it is also one of the fastest
More informationIndiabulls Housing Finance Limited Unaudited Financial Results Q1 FY July 18, 2013
Indiabulls Housing Finance Limited Unaudited Financial Results Q1 FY 2013-14 July 18, 2013 Safe Harbour Statement This document contains certain forward-looking statements based on current expectations
More informationApollo Micro Systems Ltd
IPO Note Financials Jan 08, 2018 Apollo Micro Systems Ltd Incorporated in 1997, Apollo Micro Systems Limited (AMSL) is a Hyderabad based company engaged in the business of electronic, electro-mechanical,
More informationMANPASAND BEVERAGES LTD Result Update (PARENT BASIS): Q2 FY18
MANPASAND BEVERAGES LTD Result Update (PARENT BASIS): Q2 FY18 Index Details Stock Data Sector Non-alcoholic Beverages BSE Code 539207 Face Value 10.00 52wk. High / Low (Rs.) 511.83/253.38 Volume (2wk.
More informationGeneral Insurance Corporation of India
IPO Note: General Insurance Corporation of India Industry: Insurance Reco: Subscribe Date: October 05, 2017 Issue Snapshot Company Name General Insurance Corporation of India Issue Opens October 11, 2017
More informationSandhar Technologies Limited
IPO Note Auto Ancillary Mar 15, 2018 Sandhar Technologies Limited Sandhar Technologies Ltd. is one of the leading auto component suppliers for safety and security systems such as lock assemblies, mirror
More informationAster DM Healthcare Limited
IPO NOTE Aster DM Healthcare Limited Subscribe Issue Details Listing NSE & BSE Open Date 12/2/2018 Close Date 15/2/2018 Price Band 180-190 Capital Structure (In Cr) Sh. pre-ipo 46.7 Fresh issue 3.8 Offer
More informationHCC BUY. Infrastructure April 10, QIP step in the right direction EVENT UPDATE. India Research. Bloomberg: HCC IN Reuters: HCNS.
Jan-14 Mar-14 Apr-14 May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 India Research Infrastructure April 10, 2015 EVENT UPDATE Bloomberg: IN Reuters: HCNS.BO BUY QIP step in the right direction has successfully
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 55.30 Target Price 65.00 UMANG DAIRIES LTD Result Update (PARENT BASIS): Q4 FY15 JUNE 17 th 2015 ISIN: INE864B01027 Index Details Stock Data Sector Packaged Foods BSE Code 500231 Face Value 5.00
More informationThyrocare Technologies Limited. Q2-FY18 Presentation
Thyrocare Technologies Limited Q2-FY18 Presentation Disclaimer This presentation is for information purposes only and it contains general background information about the Company s activities. The Company
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 244.05 Target Price 280.00 KALPATARU POWER TRANSMISSION LTD. Result Update (PARENT BASIS): Q3 FY15 March 2 nd 2015 ISIN: INE220B01022 Index Details Stock Data Sector Heavy Electrical Equipment
More informationWipro. 4QFY18 Result Update. Still not of the woods, maintain Hold. Sector: Technology CMP: ` 287. Recommendation: Hold
Wipro 4QFY18 Result Update Still not of the woods, maintain Hold Sector: Technology CMP: ` 287 Recommendation: Hold Market statistics Current stock price (`) 287 Shares O/S (cr.) 452.3 Mcap (` cr) 129,927
More informationACC NEUTRAL. Performance Highlights. CMP `1,261 Target Price - 4QCY2012 Result Update Cement. Quarterly results (Standalone) Investment Period -
4QCY2012 Result Update Cement February 11, 2013 ACC Performance Highlights Quarterly results (Standalone) Y/E Dec. (` cr) 4QCY2012 3QCY2012 % chg qoq 4QCY2011 % chg yoy Net sales 3,099 2,445 26.8 2,503
More informationHDFC Standard Life Insurance Company Ltd.
IPO Note: HDFC Standard Life Insurance Company Ltd. Industry: Life Insurance Recommendation: Subscribe Date: November 06, 2017 Issue Snapshot Company Name HDFC Standard Life Insurance Company Ltd. Issue
More informationNCD ISSUE Note. Aster DM Healthcare Ltd
Recommendation SUBSCRIBE BACKGROUND Price Band Rs 180-190 Company Overview Bidding Date Book Running Lead Manager Registrar Sector 12 15 Feb Kotak, Axis, GS, ISec, JM, Yes Link Intime Healthcare Minimum
More informationIndiabulls Housing Finance Limited Unaudited Financial Results Q3 FY January 22, 2014
Indiabulls Housing Finance Limited Unaudited Financial Results Q3 FY 2013-14 January 22, 2014 Safe Harbour Statement This document contains certain forward-looking statements based on current expectations
More informationVolant Textile Mills Ltd BSE Scrip Code:
Volant Textile Mills Ltd BSE Scrip Code: 531865 Textiles October 09, 2012 Equity Statistics Current Market Price Rs. 3.11 52 Week High/Low Rs. 3.55/1.34 Market Capitalisation Rs. Crores 23.31 Free Float
More informationVarroc Engineering Ltd.
IPO Note Auto ancillary June 25, 2018 Varroc Engineering Ltd. Varroc Engineering Ltd (VEL) is a tier-1 automotive component group. It designs, manufactures and supplies exterior lighting systems, plastic
More informationRecommendation BUY Snapshot CMP (01/08/2011) Rs. 85 Target Rs. 129
Recommendation BUY Snapshot CMP (01/08/2011) Rs. 85 Target Rs. 129 Sector Banking Stock Details BSE Code NSE Code Bloomberg Code Market Cap (Rs. Crs) Free Float (%) 52 wk HI/Low Avg. volume BSE (Quarterly)
More informationMahindra & Mahindra Ltd.
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 4QFY2018 Result Update Automobile May 30, 2018 Mahindra & Mahindra Ltd. Performance Update Y/E March (` cr) 4QFY18 4QFY17
More informationAmbuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)
Ambuja Cements Performance Highlights Quarterly results (Standalone) Y/E Dec. (` cr) 3QCY2015 2QCY2015 % chg qoq 3QCY2014 % chg yoy Net Sales 2,095 2,493 (16.0) 2,188 (4.2) EBIDTA 310 384 (19.2) 393 (21.2)
More informationIndustry: Banking Recommendation: Subscribe Date: August 12, 2016
IPO Note: RBL Bank Ltd. Industry: Banking Recommendation: Subscribe Date: August 12, 2016 Issue Snapshot Company Name RBL Bank Ltd. Issue Opens August 19, 2016 to August 23, 2016 Price Band Rs. 224 to
More informationAditya Gears Ltd. BSE Scrip Code:
Aditya Gears Ltd. BSE Scrip Code: 53677 Auto Parts & Equipment March 5, 23 Last Traded Price* Rs. 52 Week High/Low Rs. Market Capitalisation* Free Float Dividend Yield % One Year Regression Beta Equity
More informationCompany Overview. Financial Performance
Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 CMP: 31.25 December 24, 2015 Stock Details BSE code 523878 BSE ID TOTEX Face value ( ) 10 No of shares (m) 8.1 Market
More informationINDIAN TERRAIN FASHIONS LTD.(ITFL)
INDIAN TERRAIN FASHIONS LTD.(ITFL) Date :23 rd October, 2012 Stock Performance Details Background Current Price : Rs. 58.0** Face Value : Rs. 10 per share 52 wk High / Low : Rs. 127.00 / Rs. 47.65 Total
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 708.70 Target Price 815.00 PERSISTENT SYSTEMS LTD Result Update (CONSOLIDATED): Q4 FY15 APRIL 25 th 2015 ISIN: INE262H01013 Index Details Stock Data Sector IT BSE Code 533179 Face Value 10.00 52wk.
More informationBlue Star Ltd BUY. Performance Update. CMP Target Price `754 `867. 4QFY2018 Result Update Cons. Durable. 3-year price chart.
May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 Feb-18 May-18 4QFY2018 Result Update Cons. Durable May 16, 2018 Blue Star Ltd Performance Update 4QFY18 4QFY17 % chg. (yoy)
More informationASTRON PAPER & BOARD MILL IPO Price Band : ` 45 ` 50. our recommendation SuBScriBe
ASTRON PAPER & BOARD MILL IPO Price Band : ` 45 ` 50 our recommendation SuBScriBe THE OFFER Issue Open : 15 Dec 2017 to 20 Dec 2017»» Issue Type: Book Built Issue IPO»» Issue Size: 14,000,000 Equity Shares
More informationMRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials
Company Update Automobile February 22, 212 MRF Performance Highlights Y/E Sept. (` cr) 1QSY12 1QSY11 % chg (yoy) 4QSY11 % chg (qoq) Net sales 2,875 2,167 32.7 2,62 9.8 EBITDA 258 243 5.9 181 42.6 EBITDA
More informationBUY. NIIT TECHNOLOGIES LTD Result Update (PARENT BASIS): Q2 FY16 SYNOPSIS. CMP Target Price OCTOBER 17 th, 2015
BUY CMP 493.05 Target Price 560.00 NIIT TECHNOLOGIES LTD Result Update (PARENT BASIS): Q2 FY16 OCTOBER 17 th, 2015 ISIN: INE591G01017 Index Details Stock Data Sector IT Consulting & Software BSE Code 532541
More informationKey estimate revision. Financial summary. Year FY14 391,088 45,198 34, FY15E 354,262 35,426 23,
: price: EPS: How does our one year outlook change? We retain our negative stance on the stock. We expect s revenue to de-grow by 9% y-o-y on the back of muted execution (client side and clearance delays)
More informationPEER GROUPS CMP MARKET CAP EPS P/E (X) P/BV(X) DIVIDEND Company Name (Rs.) Rs. in mn. (Rs.) Ratio Ratio (%)
BUY CMP 2125.00 Target Price 2330.00 CERA SANITARYWARE LTD Result Update (PARENT BASIS): Q1 FY16 JULY 15 th 2015 ISIN: INE739E01017 Index Details Stock Data Sector Furniture & Furnishing BSE Code 532443
More informationGoodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials
1QCY212 Result Update Tyres June 6, 212 Goodyear India Performance Highlights Y/E December (` cr) 1QCY212 1QCY211 % chg (yoy) 4QCY211 % chg (qoq) Net sales 331 336 (1.6) 395 (16.2) EBITDA 2 24 (18.6) 34
More information